Provided herein are thiazolidinedione analogues that are useful for treating metabolic disorders and/or coronavirus infections. In some embodiments, the metabolic disorder includes insulin resistance, diabetes, or prediabetes. In some embodiments, the coronavirus is COVID-19.

The present invention relates to the use of the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate in a method of treatment or prophylaxis of vascular and respiratory disease, fibrotic disease and neurodegenerative disease, particularly interstitial pneumonia, tuberous sclerosis or lymphangioleiomyomatosis, collagen disease, interstitial lung disease, human kidney disease, nephritic syndrome, liver fibrosis or liver cirrhosis, Alzheimer's disease or Parkinson's disease.

The present invention relates to the use of the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate in a method of treatment or prophylaxis of vascular and respiratory disease, fibrotic disease and neurodegenerative disease, particularly interstitial pneumonia, tuberous sclerosis or lymphangioleiomyomatosis, collagen disease, interstitial lung disease, human kidney disease, nephritic syndrome, liver fibrosis or liver cirrhosis, Alzheimer's disease or Parkinson's disease.

The present invention relates to the use of the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate in a method of treatment or prophylaxis of vascular and respiratory disease, fibrotic disease and neurodegenerative disease, particularly interstitial pneumonia, tuberous sclerosis or lymphangioleiomyomatosis, collagen disease, interstitial lung disease, human kidney disease, nephritic syndrome, liver fibrosis or liver cirrhosis, Alzheimer's disease or Parkinson's disease.

Provided herein are compositions and methods for characterizing and treating cancer. In particular, provided herein are compositions and methods for treating cancer and identifying subjects for treatment with kinase and anti-angiogenesis inhibitors.

Provided herein are compositions and methods for characterizing and treating cancer. In particular, provided herein are compositions and methods for treating cancer and identifying subjects for treatment with kinase and anti-angiogenesis inhibitors.

The present disclosure relates to methods of inhibiting replication of a respiratory virus, and methods of treating or preventing a respiratory virus infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a N-glycosylation pathway inhibitor.

The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.

The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.

The present invention provides methods of treating obesity, pre-diabetes, diabetes, and/or obese breast cancer, by increasing mitochondrial metabolism by increasing the activity of uncoupling protein 1 (UCP1) in adipocytes. The disclosed methods comprise contacting an adrenergic receptor agonist with an adipocyte in which the genomic activity of estrogen receptor beta (ERβ) has been inhibited or inactivated. In certain aspects, inhibition or inactivation of the genomic activity of ERβ is achieved by contacting the adipocyte with an ERβ ligand that selectively inhibits or inactivates the ERβ genomic activity.